Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly 70 mg/m2 Carfilzomib in Refractory MM
NCT02294357Phase 2Terminated
- Sponsor
- ONCOtherapeutics
- Start
- Dec 2014
- Primary completion
- Sep 2020
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of carfilzomib in multiple myeloma (MM), sponsored by ONCOtherapeutics. Started Dec 2014; status: terminated.
02
Drugs
carfilzomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02294357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02294357.